ANIP - NASDAQ

ANI Pharmaceuticals, Inc.

ANIP·NASDAQ

$79.20

+5.3%

HealthcareDrug Manufacturers - Specialty & Generic

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.80B

EPS3.5000

P/E Ratio22.63

Earnings Date08/14/2026

1.44B

Assets

12%

3Y+90.0%

5Y+212.0%

10Y+346.0%

899.65M

Total Liabilities

3Y+113.0%

5Y+239.0%

10Y+487.0%

540.72M

Total Equity

26%

3Y+60.0%

5Y+176.0%

10Y+219.0%

ANI Pharmaceuticals, Inc. Funding & Solvency Profile

ANIP · NASDAQ

Current Assets

Cash & Cash Equivalents285.58M

Net Receivables281.08M

Inventory143.07M

Other Current Assets43.38M

Total Current Assets753 M

Non-Current Assets

Property, Plant & Equipment62.48M

Goodwill & Intangible Assets542.01M

Long-Term Investments0.00

Other Non-Current Assets13.71M

Total Non-Current Assets76 M

Total Assets

1.44B

Financial Health Analysis

Current Ratio

2.71x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.66x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

475 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

52% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

ANI Pharmaceuticals, Inc. Balance Sheet

ANIP • NASDAQ

ANI Pharmaceuticals, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	285.6M	144.9M	221.1M	48.2M	100.3M	7.9M	62.3M	43M	31.1M	27.4M	154.7M	169M	11.1M	34.8M	57.2M	38.2M	29.9M	11.8M	15.6M	7.7M
Short-Term Investments	0.0	6.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3M	15M	3.8M
Cash & Short-Term Investments	285.6M	151.2M	221.1M	48.2M	100.3M	7.9M	62.3M	43M	31.1M	27.4M	154.7M	169M	11.1M	34.8M	57.2M	38.2M	29.9M	14.8M	30.7M	11.4M
Net Receivables	281.1M	221.7M	162.1M	165.4M	128.5M	95.8M	72.1M	64.8M	58.8M	45.9M	21.9M	17.3M	12.5M	0.0	0.0	0.0	64.6K	229.8K	14.6K	10.5M
Accounts Receivables	281.1M	221.7M	162.1M	165.4M	128.5M	95.8M	72.1M	64.8M	58.8M	45.9M	21.9M	17.3M	12.5M	0.0	0.0	0.0	64.6K	229.8K	14.6K	10.5M
Inventory	143.1M	136.8M	111.2M	105.4M	81.7M	60.8M	48.2M	40.5M	37.7M	26.2M	13.4M	7.5M	3.5M	2.8M	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	3.8M	7.6M	5.9M	1.1M	0.0	1.2M	0.0	1.1M	1.1M	580K	378.8K	801.1K	2.5M	1.5M	1.1M	337.4K	248.1K
Other Current Assets	43.4M	18M	25.4M	21.4M	3.7M	0.0	4M	4.5M	2.8M	3.6M	1.5M	9.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Assets	753.1M	527.7M	519.8M	344.3M	321.8M	170.3M	187.7M	152.9M	131.6M	103M	192.6M	203.5M	27.7M	35.2M	58M	40.6M	31.4M	16.1M	31M	22.2M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	62.5M	56.9M	44.6M	43.2M	52.7M	41.3M	40.6M	38.1M	20.4M	11M	7.1M	5.2M	4.5M	166.4K	861.4K	635.8K	748K	814.9K	54.9K	137K
Goodwill	62.5M	60M	28.2M	28.2M	27.9M	3.6M	3.6M	3.6M	1.8M	1.8M	1.8M	1.8M	1.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	479.5M	541.8M	209M	251.6M	294.1M	188.5M	180.4M	201.6M	229.8M	175.8M	66.4M	42.1M	10.4M	85K	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	542M	601.8M	237.2M	279.9M	322M	192.1M	184M	205.2M	231.6M	177.6M	68.2M	43.9M	12.2M	85K	0.0	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	0.0	0.0	6.2M	0.0	5M	5M	0.0	5M	800K	5M	-17.3M	0.0	0.0	3.4M	3.4M	3.5M	3.6M	140K	0.0	0.0
Tax Assets	69.1M	85.1M	90.7M	81.4M	67.9M	51.7M	38.3M	28M	22.7M	26.2M	17.3M	7.8M	0.0	-85K	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	13.7M	12.2M	5.9M	11.4M	2.2M	802K	6.2M	1.5M	5M	0.0	17.3M	3.3M	0.0	15.9K	86.2K	0.0	652.7K	637.4K	179.5K	25.3K
Total Non-Current Assets	687.3M	756M	384.6M	415.8M	449.8M	290.9M	269.1M	277.7M	280.5M	219.9M	92.7M	60.2M	16.8M	3.6M	4.4M	4.1M	5M	1.6M	234.4K	162.4K
Total Assets	1.4B	1.3B	904.4M	760.1M	771.6M	461.2M	456.8M	430.6M	412.1M	322.9M	285.3M	263.7M	44.5M	38.8M	62.4M	44.8M	36.4M	17.7M	31.2M	22.4M
LIABILITIES
CURRENT LIABILITIES
Total Payables	62.6M	52.4M	44.8M	29.3M	23M	15.2M	14.6M	13.9M	3.6M	3.4M	2.1M	2.7M	1.4M	1.1M	3.2M	4.9M	2.4M	3.2M	710.6K	621.8K
Accounts Payable	62.6M	45.7M	36.7M	29.3M	23M	11.3M	14.6M	8.9M	3.6M	3.4M	2.1M	2.7M	1.4M	1.1M	3.2M	4.9M	2.4M	3.2M	710.6K	621.8K
Other Payables	0.0	6.7M	8.2M	0.0	0.0	3.9M	0.0	5M	0.0	0.0	0.0	0.0	20K	0.0	0.0	0.0	0.0	5.4K	0.0	0.0
Accrued Expenses	0.0	55.1M	34.1M	25.6M	19.4M	16.7M	16.3M	3.5M	2.3M	20.4M	1.2M	4.9M	580K	1.1M	2.5M	526K	529.1K	290.6K	795.1K	434K
Short Term Debt	17.3M	9.2M	850K	850K	850K	13.2M	9.9M	115.7M	3.4M	0.0	0.0	0.0	0.0	7.9M	0.0	1.1M	0.0	0.0	0.0	0.0
Tax Payables	11M	6.7M	8.2M	0.0	3.7M	3.9M	0.0	5M	1.2M	2.4M	1.1M	4.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	87K	80K	451K	711K	24M	0.0	0.0	0.0	47K	0.0	0.0	0.0	0.0	0.0	9.1K	68.2K
Other Current Liabilities	198.3M	77M	65.7M	43.7M	44.3M	33.4M	20.3M	31.7M	29.9M	8.2M	8.5M	5.7M	1.5M	502.5K	1.6M	1.7M	961K	374.9K	1.1K	3.2M
Total Current Liabilities	278.1M	193.7M	145.5M	99.4M	87.5M	78.6M	61.7M	165.5M	39.2M	31.9M	11.8M	13.2M	3.5M	10.6M	7.2M	8.2M	3.9M	3.9M	1.5M	4.3M
NON-CURRENT LIABILITIES
Long Term Debt	307.9M	614.9M	284.8M	285.7M	286.5M	172.4M	175.8M	67.3M	198.2M	120.6M	113.4M	110.7M	0.0	0.0	17.3M	17.4M	16.7M	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	-9.5M	-7.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	9.5M	7.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	313.6M	46.6M	16.5M	36.4M	38.8M	14.5M	6.5M	496K	0.0	625K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	621.5M	661.5M	301.3M	322.1M	325.3M	186.9M	182.3M	67.8M	198.2M	121.3M	113.4M	110.7M	0.0	0.0	17.3M	17.4M	16.7M	0.0	0.0	0.0
Total Liabilities	899.7M	855.2M	446.8M	421.5M	412.9M	265.5M	244M	233.3M	237.4M	153.2M	125.2M	123.9M	3.5M	10.6M	24.6M	25.6M	20.6M	3.9M	1.5M	4.3M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	-21M	-10.1M	-5.1M	-3.1M	-2.2M	-723K	-659K	-259K	0.0	0.0	0.0	-68K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Preferred Stock	0.0	24.9M	24.9M	24.9M	24.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	391.0	391.0	391.0	391.0	0.0	0.0	0.0
Common Stock	3K	2K	2K	1K	1K	1K	1K	1K	1K	1K	1K	1K	1K	273.1M	255.1M	184.8M	135.3M	85.7M	84.2M	65M
Additional Paid-In Capital	0.0	519.7M	514.1M	403.9M	387.8M	214.4M	200.8M	186.8M	179M	172.6M	164.4M	159.5M	89.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Retained Earnings	-23.1M	-100.3M	-80.1M	-97.3M	-47.8M	-5M	17.6M	11.5M	-4M	-2.9M	-4.4M	-19.7M	-48.5M	-245M	-217.2M	-165.6M	-119.4M	-71.9M	-54.5M	-46.9M
Accumulated Other Comprehensive Income/Loss	1M	5.3M	8.9M	12.2M	-3.1M	-11.4M	-4.9M	-379K	-6.6M	-5.4M	-4.5M	-3.8M	-3.2M	-391.6K	-426.1K	-445.8K	-347K	-209.7K	-236.9K	-769K
Other Total Stockholders' Equity	562.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	426.1K	0.0	0.0	-391.0	0.0	0.0
Total Stockholders' Equity	540.7M	428.5M	457.6M	338.5M	358.7M	195.7M	212.8M	197.3M	174.8M	169.6M	160.1M	139.8M	41M	28.2M	37.8M	19.1M	15.8M	13.8M	29.7M	18.1M
Total Equity	540.7M	428.5M	457.6M	338.5M	358.7M	195.7M	212.8M	197.3M	174.8M	169.6M	160.1M	139.8M	41M	28.2M	37.8M	19.1M	15.8M	13.8M	29.7M	18.1M
SUMMARY
Total Liabilities & Equity	1.4B	1.3B	904.4M	760.1M	771.6M	461.2M	456.8M	430.6M	412.1M	322.9M	285.3M	263.7M	44.5M	38.8M	62.4M	44.8M	36.4M	17.7M	31.2M	22.4M
Total Investments	0.0	6.3M	6.2M	0.0	5M	5M	0.0	5M	800K	5M	-17.3M	0.0	0.0	3.4M	3.4M	3.5M	3.6M	3.2M	15M	3.8M
Total Debt	325.2M	624.1M	285.7M	286.5M	287.4M	185.7M	185.7M	183M	201.5M	120.6M	113.4M	110.7M	0.0	7.9M	17.3M	18.5M	16.7M	0.0	0.0	0.0
Net Debt	39.6M	479.2M	64.5M	238.3M	187.1M	177.8M	123.4M	140M	170.4M	93.3M	-41.3M	-58.3M	-11.1M	-26.9M	-39.9M	-19.6M	-13.2M	-11.8M	-15.6M	-7.7M
Shares Outstanding	21,688,800	21,688,800	21,688,800	21,688,800	21,688,800	21,688,800	21,688,800	21,688,800	21,688,800	21,688,800	21,688,800	21,688,800	21,688,800	21,688,800	21,688,800	21,688,800	21,688,800	21,688,800	21,688,800	21,688,800

SEC Filings

ANIP - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 21, 2026	May 21, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 13, 2026	May 13, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 08, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 08, 2026	May 08, 2026	2026	View Filing
DEF 14A DEF 14A 2025 N/A	April 09, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	April 07, 2026	April 01, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 03, 2026	March 03, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 27, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 27, 2026	February 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing

Showing 1 to 10 of 461 filings

Related Guides

Blog Categories

Continue your ANIP research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.